Simple blood test could spot liver cancer sooner in at-risk patients

NCT ID NCT05971108

Recruiting now Diagnosis Sponsor: Manchester University NHS Foundation Trust Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing a blood test called Elecsys® GAAD to see if it can detect liver cancer earlier in people with liver cirrhosis. Current methods often find cancer too late, leaving few treatment options. The study will compare the GAAD test with standard care in 600 participants to see if it improves early detection and reduces unnecessary follow-up tests.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elecsys® GAAD blood test
What this could lead to: If successful, this blood test could help detect liver cancer earlier in people with cirrhosis, improving treatment options and survival chances.
What could go wrong: This is a real-world validation study, not a treatment trial. The test may not perform as well outside controlled settings, and earlier detection does not guarantee better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA LIVER CIRRHOSIS

Contacts and locations

Locations

Manchester University NHS Foundation Trust
RECRUITING

Manchester, Greater Manchester, M13 9WL, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.